Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine

BACKGROUND: This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials. METHODS: Immunogenicity data were analyzed from baseline and double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, James M, Hindiyeh, Nada, Anglin, Greg, Kalidas, Kavita, Hodsdon, Michael E, Kielbasa, William, Moser, Brian A, Pearlman, Eric M, Garces, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469706/
https://www.ncbi.nlm.nih.gov/pubmed/32340471
http://dx.doi.org/10.1177/0333102420920642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469706/
https://www.ncbi.nlm.nih.gov/pubmed/32340471
http://dx.doi.org/10.1177/0333102420920642

Ejemplares similares